JP5909554B2 - V1aアンタゴニストとしてのオキシ−シクロヘキシル−4H,6H−5−オキサ−2,3,10b−トリアザ−ベンゾ[e]アズレン類 - Google Patents
V1aアンタゴニストとしてのオキシ−シクロヘキシル−4H,6H−5−オキサ−2,3,10b−トリアザ−ベンゾ[e]アズレン類 Download PDFInfo
- Publication number
- JP5909554B2 JP5909554B2 JP2014532331A JP2014532331A JP5909554B2 JP 5909554 B2 JP5909554 B2 JP 5909554B2 JP 2014532331 A JP2014532331 A JP 2014532331A JP 2014532331 A JP2014532331 A JP 2014532331A JP 5909554 B2 JP5909554 B2 JP 5909554B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- alkoxy
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1cc(COCC(*23)=**=C2C(CC2)CCC2O*2*C2)c3cc1 Chemical compound *c1cc(COCC(*23)=**=C2C(CC2)CCC2O*2*C2)c3cc1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11182796.0 | 2011-09-26 | ||
EP11182796 | 2011-09-26 | ||
PCT/EP2012/068721 WO2013045373A1 (en) | 2011-09-26 | 2012-09-24 | Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014527993A JP2014527993A (ja) | 2014-10-23 |
JP5909554B2 true JP5909554B2 (ja) | 2016-04-26 |
Family
ID=46881068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014532331A Active JP5909554B2 (ja) | 2011-09-26 | 2012-09-24 | V1aアンタゴニストとしてのオキシ−シクロヘキシル−4H,6H−5−オキサ−2,3,10b−トリアザ−ベンゾ[e]アズレン類 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8828989B2 (ru) |
EP (1) | EP2760871B1 (ru) |
JP (1) | JP5909554B2 (ru) |
KR (1) | KR101682777B1 (ru) |
CN (1) | CN103827121B (ru) |
AR (1) | AR087999A1 (ru) |
AU (1) | AU2012314593B2 (ru) |
BR (1) | BR112014006945A2 (ru) |
CA (1) | CA2844581A1 (ru) |
CL (1) | CL2014000717A1 (ru) |
CO (1) | CO6870036A2 (ru) |
CR (1) | CR20140092A (ru) |
EA (1) | EA024990B1 (ru) |
EC (1) | ECSP14013271A (ru) |
IN (1) | IN2014CN02169A (ru) |
MA (1) | MA35535B1 (ru) |
MX (1) | MX2014003643A (ru) |
PE (1) | PE20141397A1 (ru) |
SG (1) | SG2014010607A (ru) |
TW (1) | TWI553013B (ru) |
UA (1) | UA111623C2 (ru) |
WO (1) | WO2013045373A1 (ru) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69911259T4 (de) | 1999-01-19 | 2009-07-09 | Ortho-Mcneil Pharmaceutical, Inc. | Tricyclische benzodiazepine als vasopressin antagonisten |
US6765004B1 (en) | 1999-06-17 | 2004-07-20 | Ortho-Mcneil Pharmaceutical, Inc. | Indoloazepines as vasopressin receptor antagonists |
GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
US7119088B2 (en) | 2003-02-19 | 2006-10-10 | Pfizer Inc. | Triazole compounds useful in therapy |
GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
WO2006021882A1 (en) * | 2004-08-25 | 2006-03-02 | Pfizer Limited | Triazolobenzodiazepines and their use as vasopressin antagonists |
PE20110590A1 (es) * | 2008-11-18 | 2011-08-31 | Hoffmann La Roche | Alquilciclohexileteres de dihidrotetraazabenzoazulenos |
PL2370441T3 (pl) | 2008-11-28 | 2014-02-28 | Hoffmann La Roche | Arylocykloheksyloetery dihydrotetraazabenzoazulenów do stosowania jako antagoniści receptora v1a wazopresyny |
-
2012
- 2012-08-23 US US13/592,493 patent/US8828989B2/en active Active
- 2012-09-24 EA EA201490558A patent/EA024990B1/ru not_active IP Right Cessation
- 2012-09-24 JP JP2014532331A patent/JP5909554B2/ja active Active
- 2012-09-24 UA UAA201403611A patent/UA111623C2/uk unknown
- 2012-09-24 PE PE2014000394A patent/PE20141397A1/es not_active Application Discontinuation
- 2012-09-24 KR KR1020147010783A patent/KR101682777B1/ko active IP Right Grant
- 2012-09-24 EP EP12761740.5A patent/EP2760871B1/en active Active
- 2012-09-24 WO PCT/EP2012/068721 patent/WO2013045373A1/en active Application Filing
- 2012-09-24 IN IN2169CHN2014 patent/IN2014CN02169A/en unknown
- 2012-09-24 SG SG2014010607A patent/SG2014010607A/en unknown
- 2012-09-24 MX MX2014003643A patent/MX2014003643A/es unknown
- 2012-09-24 CN CN201280046689.0A patent/CN103827121B/zh active Active
- 2012-09-24 BR BR112014006945A patent/BR112014006945A2/pt not_active IP Right Cessation
- 2012-09-24 CA CA2844581A patent/CA2844581A1/en not_active Abandoned
- 2012-09-24 AU AU2012314593A patent/AU2012314593B2/en not_active Ceased
- 2012-09-25 AR ARP120103514A patent/AR087999A1/es unknown
- 2012-09-25 TW TW101135168A patent/TWI553013B/zh not_active IP Right Cessation
-
2014
- 2014-01-31 CO CO14020668A patent/CO6870036A2/es not_active Application Discontinuation
- 2014-02-26 CR CR20140092A patent/CR20140092A/es unknown
- 2014-03-24 CL CL2014000717A patent/CL2014000717A1/es unknown
- 2014-03-26 EC ECSP14013271 patent/ECSP14013271A/es unknown
- 2014-04-15 MA MA36919A patent/MA35535B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2012314593A1 (en) | 2014-02-20 |
MA35535B1 (fr) | 2014-10-02 |
SG2014010607A (en) | 2014-05-29 |
CN103827121B (zh) | 2016-08-03 |
KR20140079790A (ko) | 2014-06-27 |
UA111623C2 (uk) | 2016-05-25 |
AR087999A1 (es) | 2014-04-30 |
BR112014006945A2 (pt) | 2017-04-04 |
WO2013045373A1 (en) | 2013-04-04 |
CA2844581A1 (en) | 2013-04-04 |
EA201490558A1 (ru) | 2014-06-30 |
CR20140092A (es) | 2014-03-20 |
MX2014003643A (es) | 2014-04-30 |
EA024990B1 (ru) | 2016-11-30 |
AU2012314593A8 (en) | 2014-03-27 |
AU2012314593B2 (en) | 2016-09-29 |
IN2014CN02169A (ru) | 2015-05-29 |
JP2014527993A (ja) | 2014-10-23 |
TWI553013B (zh) | 2016-10-11 |
CO6870036A2 (es) | 2014-02-20 |
EP2760871B1 (en) | 2018-07-18 |
ECSP14013271A (es) | 2014-05-31 |
TW201315737A (zh) | 2013-04-16 |
NZ620653A (en) | 2016-03-31 |
US8828989B2 (en) | 2014-09-09 |
US20130079333A1 (en) | 2013-03-28 |
KR101682777B1 (ko) | 2016-12-05 |
PE20141397A1 (es) | 2014-10-13 |
EP2760871A1 (en) | 2014-08-06 |
CL2014000717A1 (es) | 2014-10-03 |
CN103827121A (zh) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5384659B2 (ja) | ジヒドロテトラアザベンゾアズレンのアルキルシクロヘキシルエーテル | |
JP5579923B2 (ja) | バソプレシンV1a受容体アンタゴニストとしてのヘテロアリール−シクロヘキシル−テトラアザベンゾ[e]アズレン | |
JP5599936B2 (ja) | アリール−シクロヘキシル−テトラアザベンゾ[e]アズレン | |
JP5452608B2 (ja) | バソプレシン介在受容体アンタゴニストとしての使用のためのジヒドロテトラアザベンゾアズレンのアリールシクロヘキシルエーテル | |
KR101468285B1 (ko) | 바소프레신 길항제로서의 아릴-/헤테로아릴-사이클로헥센일-테트라아자벤조〔e〕아줄렌 | |
US9346824B2 (en) | Cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes as V1a antagonists | |
JP5579925B2 (ja) | ヘテロビアリール−シクロヘキシル−テトラアザベンゾ[e]アズレン | |
JP5909554B2 (ja) | V1aアンタゴニストとしてのオキシ−シクロヘキシル−4H,6H−5−オキサ−2,3,10b−トリアザ−ベンゾ[e]アズレン類 | |
NZ620653B2 (en) | Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150106 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160301 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160328 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5909554 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |